Nymox Pharmaceutical income statement data for the quarter ended Dec 2025. This income statement covers 32 quarters of results from Dec 2016 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Dec2016 | Mar2017 | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Sep2024 | Dec2024 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||||||||
| Revenue | 0.03M | 0.01M | ||||||||||||||||||||||||||||||
| Cost of RevenueCost of Rev | 0.01M | 0.00M | ||||||||||||||||||||||||||||||
| Gross Profit | 0.02M | 0.00M | ||||||||||||||||||||||||||||||
| Operating items | ||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 1.80M | 1.56M | 2.16M | 3.24M | 1.17M | 1.43M | 2.07M | 1.84M | 1.33M | 4.33M | 0.81M | 0.89M | -2.26M | 0.72M | 0.59M | 0.66M | 2.02M | 0.51M | 0.62M | |||||||||||||
| Selling, General & AdministrativeSG&A | 0.92M | 1.08M | 0.77M | 0.91M | 0.84M | 1.00M | 1.91M | 1.46M | 1.48M | 0.74M | 0.96M | 0.59M | 0.59M | 0.67M | 0.51M | 0.35M | 2.83M | 0.14M | 0.16M | |||||||||||||
| Operating ExpensesOpex | 2.73M | 2.63M | 2.93M | 4.14M | 2.02M | 2.43M | 3.98M | 3.29M | 2.80M | 5.07M | 1.77M | 1.48M | -1.67M | 1.39M | 1.10M | 1.01M | 4.85M | 0.65M | 0.79M | |||||||||||||
| Operating IncomeOp. Inc | -2.71M | -2.63M | -2.93M | -4.14M | -2.02M | -2.43M | -3.98M | -3.29M | -2.80M | -5.07M | -1.77M | -1.48M | 1.67M | -1.39M | -1.10M | -1.01M | -4.85M | -0.65M | -0.79M | |||||||||||||
| EBIT | -2.71M | -2.63M | -2.93M | -4.14M | -2.02M | -2.43M | -3.98M | -3.29M | -2.80M | -5.07M | -1.77M | -1.48M | 1.67M | -1.39M | -1.10M | -1.01M | -4.85M | -0.65M | -0.79M | |||||||||||||
| Non-operating items | ||||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | -0.13M | 0.01M | 0.00M | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M | 0.01M | 0.02M | 0.03M | 0.06M | 0.09M | |||||||||||||||||||
| Net income details | ||||||||||||||||||||||||||||||||
| EBT | -2.58M | -2.62M | -2.94M | -4.16M | -2.03M | -2.44M | -3.99M | -3.30M | -2.81M | -5.09M | 1.34M | -1.49M | -1.34M | -1.39M | -1.11M | -1.04M | -5.31M | -0.72M | -0.86M | |||||||||||||
| Profit After TaxPAT | -2.58M | -2.62M | -2.94M | -4.16M | -2.03M | -2.44M | -3.99M | -3.30M | -2.81M | -5.09M | 1.34M | -1.49M | -1.34M | -1.39M | -1.11M | -1.04M | -5.31M | -0.72M | -0.86M | |||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -2.58M | -2.62M | -2.94M | -4.16M | -2.03M | -2.44M | -3.99M | -3.30M | -2.81M | -5.09M | 1.34M | -1.49M | -1.34M | -1.39M | -1.11M | -1.04M | -5.31M | -0.72M | -0.86M | |||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -2.69M | -2.62M | -2.94M | -4.16M | -2.03M | -2.44M | -3.99M | -3.30M | -2.81M | -5.09M | 1.34M | -1.49M | -1.34M | -1.39M | -1.11M | -1.04M | -5.31M | -0.72M | -0.86M | |||||||||||||
| Income towards Parent CompanyParent Net Inc | -2.69M | -2.62M | -2.94M | -4.16M | -2.03M | -2.44M | -3.99M | -3.30M | -2.81M | -5.09M | 1.34M | -1.49M | -1.34M | -1.39M | -1.11M | -1.04M | -5.31M | -0.72M | -0.86M | |||||||||||||
| Net Income towards Common StockholdersNet Income | -2.69M | -2.62M | -2.94M | -4.16M | -2.03M | -2.44M | -3.99M | -3.30M | -2.81M | -5.09M | 1.34M | -1.49M | -1.34M | -1.39M | -1.11M | -1.04M | -5.31M | -0.72M | -0.86M | |||||||||||||
| Additional items | ||||||||||||||||||||||||||||||||
| EPS (Basic) | -0.04 | -0.04 | -0.04 | -0.06 | -0.03 | -0.03 | -0.05 | -0.04 | -0.03 | -0.06 | 0.02 | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 | -0.06 | -0.01 | -0.01 | |||||||||||||
| Shares Outstanding | 68.85M | 68.85M | 68.85M | 68.85M | 73.82M | 73.82M | 73.82M | 73.82M | 81.98M | 81.98M | 81.98M | 81.98M | 89.38M | 89.38M | 89.38M | 89.38M | 91.69M | 91.69M | 93.67M | 96.04M | ||||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 71.22M | 77.96M | 85.55M | 90.52M | 93.54M | 94.54M | 102.04M | |||||||||||||||||||||||||
| EBITDA | -2.71M | -2.63M | -2.93M | -4.14M | -2.01M | -2.43M | -3.98M | -3.29M | -2.80M | -5.07M | -1.77M | -1.48M | 1.68M | -1.38M | -1.10M | -1.01M | -4.85M | -0.79M | ||||||||||||||
| Interest ExpensesInt Expense | -0.13M | 0.01M | 0.00M | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M | 0.01M | 0.02M | 0.03M | 0.06M | 0.09M |
Pull Nymox Pharmaceutical's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=NYMXF&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "NYMXF", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=NYMXF&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();